NCT00065429View on ClinicalTrials.gov

Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2008

Conditions
Small Cell Lung Cancer
Interventions
DRUG

BB-10901

"I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease."

Trial Locations (11)

12208

New York Oncology Hematology, Albany

23502

Virginia Oncology Associates, Norfolk

29605

Cancer Centers of the Carolinas, Greenville

34761

Cancer Center of Florida, Ocoee

43221

The Ohio State University, Colombus

45409

Greater Dayton Cancer Center, Kettering

75702

Tyler Cancer Center, Tyler

80218

Rocky Mountain Cancer Centers, Denver

98684

Northwest Cancer Specialists, Vancouver

01107

Baystate Medical Center, Springfield

77030-7095

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

ImmunoGen, Inc.
All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY